Tyra Biosciences Inc logo

Tyra Biosciences Inc

TYRA
Healthcare|Biotechnology|USA
$32.75
-0.26 (-0.79%)
Tangible Book
$6.52
Earnings Power
$6.02

About

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Stock Price

+219.8%(1Y)

Pipeline Summary

8 total trials
4
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 5Active: 2Completed: 1

Active Trials (7)

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947Low Grade Upper Tract Urothelial Carcinoma
Phase 2Recruiting
Enrollment: 230 participants
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355Achondroplasia
Phase 2Recruiting
Enrollment: 92 participants
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552Locally Advanced Urothelial Carcinoma
Phase 1Phase 2Active
Enrollment: 310 participants
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma
Phase 1Recruiting
Enrollment: 100 participants
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677Low-grade NMIBC
Phase 2Recruiting
Enrollment: 90 participants
View all 7 active trials →

BioScore

4.6/10
Cautious

Ownership

Recent Insider Trades

KAPLAN GILLASELL
2026-03-2514,295 shares @ $36.97
Bensen DanielSELL
2026-02-128,000 shares @ $32.87
Bensen DanielSELL
2026-01-128,000 shares @ $28.52
MORE ROBERT JSELL
2025-12-1910,000 shares @ $25
Bensen DanielSELL
2025-12-128,000 shares @ $22.64

Recent News

2026-06-17 14:30:39
Data last updated: Jul 13, 2026, 12:44 PM